Fiera Capital Corp Invests $13.98 Million in Biohaven Ltd. (NYSE:BHVN)

Fiera Capital Corp purchased a new position in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 581,675 shares of the company's stock, valued at approximately $13,983,000. Fiera Capital Corp owned 0.57% of Biohaven as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in BHVN. Parallel Advisors LLC lifted its holdings in Biohaven by 319.8% during the 1st quarter. Parallel Advisors LLC now owns 1,360 shares of the company's stock worth $33,000 after purchasing an additional 1,036 shares in the last quarter. IFP Advisors Inc lifted its holdings in Biohaven by 84,800.0% during the 1st quarter. IFP Advisors Inc now owns 2,547 shares of the company's stock worth $61,000 after purchasing an additional 2,544 shares in the last quarter. KBC Group NV lifted its holdings in Biohaven by 35.0% during the 1st quarter. KBC Group NV now owns 4,560 shares of the company's stock worth $110,000 after purchasing an additional 1,183 shares in the last quarter. Quarry LP purchased a new stake in Biohaven during the 4th quarter worth about $112,000. Finally, Lazard Asset Management LLC lifted its holdings in Biohaven by 47.4% during the 4th quarter. Lazard Asset Management LLC now owns 3,207 shares of the company's stock worth $119,000 after purchasing an additional 1,031 shares in the last quarter. Institutional investors own 88.78% of the company's stock.

Wall Street Analysts Forecast Growth

BHVN has been the topic of a number of recent research reports. JPMorgan Chase & Co. dropped their price objective on Biohaven from $68.00 to $55.00 and set an "overweight" rating on the stock in a report on Wednesday, June 18th. Royal Bank Of Canada cut Biohaven from an "outperform" rating to a "sector perform" rating and lowered their price target for the company from $54.00 to $21.00 in a report on Monday, May 19th. Cantor Fitzgerald raised Biohaven to a "strong-buy" rating in a report on Tuesday, May 13th. William Blair raised Biohaven to a "strong-buy" rating in a report on Thursday, April 24th. Finally, Robert W. Baird lowered their price target on Biohaven from $60.00 to $57.00 and set an "outperform" rating on the stock in a report on Monday, April 28th. One investment analyst has rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $58.46.

Biohaven Stock Performance

BHVN traded down $0.33 on Friday, hitting $14.77. 2,462,789 shares of the company were exchanged, compared to its average volume of 1,674,660. The firm has a fifty day simple moving average of $14.72 and a two-hundred day simple moving average of $23.73. Biohaven Ltd. has a 12 month low of $12.79 and a 12 month high of $55.70. The stock has a market capitalization of $1.51 billion, a PE ratio of -1.58 and a beta of 0.91.

Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($2.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.50). On average, equities analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.